BioCentury | May 29, 2020
Distillery Therapeutics

Epigenetic protein PHF20L1 identified as breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting PHF20L1, an epigenetic protein that recognizes methylated histone residues, could treat breast cancer. In breast cancer patients, high tumor levels of PHF20L1 protein were associated with high histological...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BioCentury | Jun 21, 2017
Distillery Therapeutics

Neurology

INDICATION: Anxiety; depression Mouse studies suggest inhibiting PHF8 could help treat anxiety and depression. In two mouse models of anxiety, systemic PHF8 knockout decreased anxiety-like behaviors compared with normal expression. In two mouse models of...
BioCentury | Apr 4, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute promyelocytic leukemia (APL) PHD finger protein 8 (PHF8) In vitro and mouse studies suggest activating PHF8 could help restore sensitivity...
BioCentury | Sep 6, 2012
Targets & Mechanisms

Passenger mutations take the wheel

Two research groups have independently shown that targeting genes carrying passenger mutations blocked growth of cancer cells and improved survival in mouse models. 1,2 Although precise therapeutic windows for such a strategy remain to be...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) PHD finger protein 6 (PHF6) Genetic sequencing studies identified PHF6...
...treat T cell ALL. Mutational analysis of patient samples identified variants that caused loss of PHF6...
...expression in 16% of pediatric and 38% of adult cases of T cell ALL. The PHF6...
BioCentury | Feb 6, 2006
Product Development

Breathless opportunities

Treatment of asthma has remained essentially unchanged for years and focuses on alleviating symptoms rather than disease modification. In large part, the state of the art reflects inertia on the part of the dominant big...
BioCentury | Apr 19, 1999
Company News

CV Tech, Shield deal

SDG will exclusively develop and market, except in Japan, CV's parathyroid hypertensive factor (PHF) test kit to manage hypertension. SDG will pay CV a $30,000 upfront fee, and is responsible for clinical and regulatory requirements....
Items per page:
1 - 10 of 10